Cessation of intensive treatment with recombinant human erythropoietin (rHuEpo) Is followed by secondary anemia
2000; Elsevier BV; Volume: 28; Issue: 7 Linguagem: Inglês
10.1016/s0301-472x(00)00261-7
ISSN1873-2399
AutoresMaude Piron, Martine Loo, André Gothot, Françoise Tassin, Georges Fillet, Yves Béguin,
Tópico(s)Erythropoietin and Anemia Treatment
ResumoAbstract Little information is available on the evolution of hematological parameters after cessation of intensive treatment with rHuEpo. Groups of 3–5 rats were iron overloaded to avoid functional iron deficiency and received daily IV injections of 150 U rHuEpo for 20 days. During treatment, reticulocytes, soluble transferrin receptor (sTfR, a quantitative measure of total erythropoiesis) and Hct increased progressively (p
Referência(s)